Victoza: Victoza reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events

A new analysis of the landmark LEADER trial shows that Victoza liraglutide reduced the risk of major cardiovascular CV events in people with type 2 diabetes at high CV risk irrespective of their history of having a heart attack andor stroke or not having ...